



# landmARCC

Marking a turning point...

## JOIN US

**ARCC Conference**  
**May 8-9, 2016**  
**Toronto, ON**

Check the website [www.cc-arcc.ca](http://www.cc-arcc.ca) or follow us on Twitter (@cc\_arcc) or LinkedIn for updates about registration and abstract submission

## Directors' Message

Welcome to the Summer 2015 issue of landmARCC!

On May 24th and 25th 2015, we hosted the 4th Applied Research in Cancer Control Conference in Montréal, Québec. It was another resounding success with 79 poster and oral presentations from submitted abstracts. This year we offered a special “Fireside Chat” session on cancer drug funding and access, brought back the popular Speed Networking event, and welcomed conference co-chairs for the first time. We are deeply grateful to our co-chairs, Drs. Alice Dragomir and Jean Rousseau, for helping make our conference a success! More information about the 2015 ARCC Conference can be found in this issue, and many of the conference presentations are available to ARCC members on our website (if you need help logging in, please contact Rebecca Mercer using the [ARCC@cancercare.on.ca](mailto:ARCC@cancercare.on.ca) email address). We look forward to next year’s conference on May 8th and 9th in Toronto, Ontario, and hope you will join us there!

We want to take a moment to thank everyone who completed the 2015 ARCC Conference evaluation form and provided us with some excellent ideas for future conferences. If you were unable to attend this year’s conference but still have some suggestions (e.g., featured topics, workshop possibilities), or if you would like to get involved in future ARCC conferences, please reach out to us at the above email address. We would love to have your input.

Thank you for helping make ARCC the great network community it has become!

Sincerely,  
 Jeffrey and Stuart

### This issue of landmARCC

- Directors' Message
- ARCC Conference 2015
- Upcoming Events
- Member Spotlight
- Recent Publications
- Congratulations

Do you want to share information in a future newsletter?  
 If so, please contact [ARCC@cancercare.on.ca](mailto:ARCC@cancercare.on.ca)



ARCC co-directors  
 Dr. Stuart Peacock  
 (left) & Dr. Jeffrey  
 Hoch (right)

## Highlights from the 4th Applied Research in Cancer Control Conference

- Over 125 registered participants representing eight provinces
  - 32 people participating in our Speed Networking event
  - Over 40 participants in our Fireside Chat “Cancer Drug Funding and Access: Different Perspectives” – Big thanks to Mona Sabharwal (pCODR) and Charlotte Chamberlain (University of Bristol) for participating
  - Six Keynote speakers – Thank you to Drs. Andrew Loblaw, Fernand Turcotte, Craig Earle, Raghu Rajan, Mr. Rocco Rossi, and Ms. Chantal Kroon 30 oral and 49 poster presentations from submitted abstracts
- Keynote, oral, and poster presentations can be found on our website at <http://cc-arcc.ca/conference-presentations-2015/> \*

*\*You must be logged on to the ARCC website to access conference presentations. If you do not have and/or need assistance setting up a web login, please contact Rebecca Mercer at [ARCC@cancercare.on.ca](mailto:ARCC@cancercare.on.ca)*





### Congratulations to our Student Travel Award winners

- Katherine Jensen, Alberta Health Services
- Daniel Kagedan, University of Toronto
- Wyanne Law, University of Ottawa
- Ning Liu, University of Toronto
- Ciara Pendrith, Princess Margaret Cancer Centre
- Linwei Wang, University of Alberta



### Congratulations to our Poster Award winners

Jason Hu (Student competition winner) – Poster title: *Health services utilization in the end-of-life phase of patients dying of prostate cancer in Quebec between 2001 and 2013*

Sharon Kirkpatrick (General competition winner) – Poster title: *Advancing evidence-based dietary assessment in Canada to enhance cancer prevention and survivorship research*



Our next conference will be held in Toronto, Ontario on Sunday May 8th and Monday May 9th. Stay tuned to the ARCC Website for more details.

## Upcoming Events

### ARCC Webinars

We encourage you to participate in our webinars. This is an excellent opportunity to get involved, learn about current research projects and methods, connect with other researchers and discuss future research initiatives.

---

**Friday, September 18, 2015**

Patient and caregiver experience at end of life:  
Results from the CaregiverVoice survey

**Presenter: Dr. Hsien Seow**

**1:00pm – 2:00pm (EST) 10:00am – 11:00am (PST)**  
**2:00pm – 3:00pm (AST) 11:00am – 12:00pm (MST)**

---

**Friday, October 9, 2015**

Health Economics and Prostate Cancer

**Presenter: Dr. Alice Dragomir**

**1:00pm – 2:00pm (EST) 10:00am – 11:00am (PST)**  
**2:00pm – 3:00pm (AST) 11:00am – 12:00pm (MST)**



Calendar reminders will be emailed to the ARCC Network directly and can be found on our website at <http://cc-arcc.ca/webinars/>, along with additional details and information about previous webinars.

Interested in presenting an ARCC Webinar?

Please contact us with your ideas today

**ARCC@cancercare.on.ca**



### Member Spotlight

Jason Hu is currently a second year Master of Science (MSc) student in health economics and outcomes research in the Experimental Surgery program at McGill University and working with Dr. Alice Dragomir. He grew up in Montréal, QC and has always lived there. Congratulations to Jason, who

received the ARCC Conference Student Poster Award at our recent conference for his poster titled *Health services utilization in the end-of-life phase of patients dying of prostate cancer in Québec between 2001 and 2013*.

#### Describe your current training/how you will continue when you complete your current program.

I completed a Bachelor of Science (BSc) degree in Biopharmaceutical Sciences at Université de Montréal, during which I learned about the drug development process from the preclinical stage to the post-marketing area. The courses I've taken during my MSc, as well as the training I have received from Dr. Dragomir, have furthered my knowledge in epidemiology, health economics and outcomes research. After completion of my thesis, I hope to pursue a doctoral degree.

#### What are your current research projects and research interests?

My research is based out of the Division of Urology at McGill University and my main focus is on prostate cancer. My interests in health economics and outcomes research began during my undergraduate degree, where I learned about the divergence of efficacy seen in clinical trials from the real-world effectiveness of treatments. My current main project focuses on the impact of initial local primary treatment on the risk of loco-regional complications in castration-resistant prostate cancer patients. For this project, I am using a large administrative database from the Régie de l'assurance de maladie du Québec (RAMQ). My project is part of a larger project for which Dr. Dragomir, as principal investigator, received funding from Prostate Cancer Canada – Discovery Grant 2013. Additionally, I am working on a project that seeks to compare conventional fractionation to hypofractionation of radiotherapy in prostate cancer.

#### What is your favourite hobby?

I enjoy strength training in general and in particular Olympic-style weightlifting. I am also an avid follower of the NBA.

## Recent Publications

Do you have a recent publication you would like us to list here? Please send the details to [ARCC@cancercare.on.ca](mailto:ARCC@cancercare.on.ca)

*Authors names in bold indicate ARCC membership*

**Barbera L, Seow H, Sutradhar R, Chu A, Burge F, Fassbender K, McGrail K, Lawson B, Liu Y, Pataky R, Potapov A.** Quality Indicators of End-of-Life Care in Patients With Cancer: What Rate Is Right?. *J Oncol Pract.* 2015;11(3):e279-87.

**Bombard Y, Rozmovits L, Trudeau M, Leighl NB, Deal K, Marshall DA.** The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment. *Oncologist.* 2015;20(4):351-356.

**Cheung MC, Earle CC, Rangrej J, Rangrej J, Ho TH, Liu N, Barbera L, Saskin R, Porter J, Seung SJ, Mittmann N.** Impact of aggressive management and palliative care on cancer costs in the final month of life. *Cancer.* 2015 May 29 [Epub ahead of print].

**Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer D, Desjardins P, Shepherd L, Meyer RM, Le A, Chen BE, Mittmann N;** Committee on Economic Analysis and the Hematology Disease Site Committee, NCIC Clinical Trials Group. Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. *J Natl Cancer Inst.* 2015;107(7).

**Cressman S, Browman GP, Hoch JS, Kovacic L, Peacock SJ.** A Time-Trend Economic Analysis of Cancer Drug Trials. *Oncologist.* 2015; 20(7):729-736.

**Cromwell I, Peacock SJ, Mitton C.** 'Real-world' health care priority setting using explicit decision criteria: a systematic review of the literature. *BMC Health Serv Res.* 2015;15:164.

**Djalalov S, Beca J, Amir E, Krahn M, Trudeau ME, Hoch JS.** Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada. *Curr Oncol.* 2015;22(2):84-96.

**Graham DM, Isaranuwatthai W, Habbous S, de Oliveira C, Liu G, Siu LL, Hoch JS.** A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. *Cancer.* 2015;121(11):1785-92.

**Grendarova P, Sinnarajah A, Trotter T, Card C, Wu JS.** Variations in intensity of end-of-life cancer therapy by cancer type at a Canadian tertiary cancer centre between 2003 and 2010. *Support Care Cancer.* 2015 Mar 7 [Epub ahead of print].

**Guerriere D, Husain A, Zagorski B, Marshall D, Seow H, Brazil K, Kennedy J, Burns S, Brooks H, Coyte PC.** Predictors of caregiver burden across the home-based palliative care trajectory in Ontario, Canada. *Health Soc Care Community.* 2015 Mar 25 [Epub ahead of print]. **Hoch JS, Beca J, Sabharwal M, Livingstone SW, Fields AL.** Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?. *Pharmacoeconomics.* 2015 May 5 [Epub ahead of print].

**Mühlberger N, Kurthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.** The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening. *Med Decis Making.* 2015 May 14 [Epub ahead of print].

**Su J, Barbera L, Sutradhar R.** Do repeated assessments of performance status improve predictions for risk of death among patients with cancer? A population-based cohort study. *Palliat Med.* 2015;29(6):547-553.

**Torres S, Trudeau M, Eisen A, Earle CC, Chan KK.** Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. *Breast Cancer Res Treat.* 2015;152(1):137-45.

## Congratulations

Do you know an ARCC Member who deserves to be acknowledged for a recent accomplishment? Please send the details to [ARCC@cancercare.on.ca](mailto:ARCC@cancercare.on.ca)

- Dr. Yvonne Bombard for receiving a CIHR Foundation Grant supporting advances in genomic technologies
- Dr. Nicole Mittmann, ARCC Investigator, for her new position as Chief Research Officer for Cancer Care Ontario.
- Dr. Stuart Peacock, ARCC Co-Director, on being named as the Inaugural Leslie Diamond Chair in Cancer Survivorship at Simon Fraser University. [Read the official news release online here.](#)
- Dr. Dean Regier, on his new appointment as Scientist with ARCC-BC. Dean's research will have a personalized medicine focus, and will be featured in our next newsletter. We extend a special thank you to CCSRI and the BC Cancer Agency for supporting and enabling this appointment.